Paolo Pucci
Director/Board Member at WEST PHARMACEUTICAL SERVICES, INC.
Net worth: 4 M $ as of 2024-03-30
Profile
Paolo Pucci is currently the Lead Independent Director at West Pharmaceutical Services, Inc. He also holds positions as an Independent Non-Executive Director at Merus NV, an Independent Director at Replimune Group, Inc., and an Independent Director at Tarus Therapeutics, Inc. Previously, Mr. Pucci served as the Chief Executive Officer & Director at ArQule, Inc. from 2008 to 2020.
He was also an Independent Director at Dyax Corp.
from 2011 to 2016, and an Independent Director at NewLink Genetics Corp.
from 2015 to 2018.
Additionally, he held the position of Lead Independent Director at Trillium Therapeutics ULC from 2020 to 2021, and was a Non-Executive Director at Algeta ASA from 2013 to 2014.
Mr. Pucci has a background in business, having served as the Managing Director at Eli Lilly Sweden AB and as the Senior VP-Global Specialty Medicine Business Unit at Bayer AG from 2001 to 2008.
He also held the position of President-US Pharmaceutical Operations at Bayer Pharmaceuticals Corp.
and was a Senior Vice President at Bayer Pharma AG.
Mr. Pucci completed his undergraduate studies at Università degli Studi di Napoli Federico II and holds an MBA from The University of Chicago Booth School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-04-24 | 9,311 ( 0.01% ) | 4 M $ | 2024-03-30 | |
REPLIMUNE GROUP, INC.
-.--% | 2024-03-31 | 0 ( -.--% ) | - $ | 2024-03-30 |
MERUS N.V.
-.--% | 2023-06-07 | 0 ( -.--% ) | - $ | 2024-03-30 |
Paolo Pucci active positions
| Companies | Position | Start |
|---|---|---|
| WEST PHARMACEUTICAL SERVICES, INC. | Director/Board Member | 2016-09-11 |
| REPLIMUNE GROUP, INC. | Director/Board Member | 2020-03-31 |
| MERUS N.V. | Director/Board Member | 2020-06-29 |
Tarus Therapeutics, Inc.
 Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Director/Board Member | 2020-12-01 |
Former positions of Paolo Pucci
| Companies | Position | End |
|---|---|---|
| TRILLIUM THERAPEUTICS | Director/Board Member | 2021-11-16 |
| LUMOS PHARMA, INC. | Director/Board Member | 2018-10-30 |
| DYAX CORP. | Director/Board Member | 2016-01-21 |
| ALGETA ASA | Director/Board Member | 2014-02-28 |
| BAYER AG | Corporate Officer/Principal | 2008-05-31 |
Training of Paolo Pucci
| Università degli Studi di Napoli Federico II | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| BAYER AG | Health Technology |
| WEST PHARMACEUTICAL SERVICES, INC. | Health Technology |
| MERUS N.V. | Health Technology |
| Private companies | 10 |
|---|---|
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
| Bayer Pharmaceuticals Corp. | |
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Bayer Pharma AG
 Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany. | Health Technology |
| Eli Lilly Sweden AB | |
| Replimune Group, Inc. | |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
- Stock Market
- Insiders
- Paolo Pucci
